Get informed when a big investor buys or sells
+ FollowOctober 22, 2026 - AI Summary
Overvalued by 92.3% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $24.03 Billion |
|---|---|
| Enterprise Value | $26.38 Billion |
| Annual dividend | $0.80 |
| Dividend yield | 0.31% |
| Earnings per Share | $2.73 |
| Beta | 1.15 |
| Outstanding Shares | 97,296,419 |
| P/E Ratio | 66.83 |
|---|---|
| PEG | 145.48 |
| Price to Sales | 7.97 |
| Price to Book Ratio | 5.49 |
| Enterprise Value to Revenue | 8.61 |
| Enterprise Value to EBIT | 23.19 |
| Enterprise Value to Net Income | 83 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.57 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental...